Medical Systems
 |
The new Crosslinking "TAD CXL" system from TAD medical
Crosslinking has been used successfully for many years for the treatment of keratoconus, a conical protrusion of the cornea caused by insufficient corneal stability.
The procedure is based on a crosslinking of collagen fibers in the cornea with the help of riboflavin and irradiation with UV-A light. This crosslinking stabilizes the corneal tissue.
The goal is to stop the progression of keratoconus at the earliest possible stage.
The method was researched and developed in Dresden in the 1990s.
The company TAD produced the first commercial CXL system on the market.
The new "TAD CXL" system is a new development and offers the possibility to choose between significantly extended treatment parameters.
Many years now, Crosslinking has been successful in the treatment of keratoconus, a conical protrusion of the cornea caused by insufficient corneal stability.
The Crosslinking procedure stabilizes the corneal tissue by a crosslinking of collagen fibers in the cornea with the help of riboflavin and irradiation with UV-A light.
The goal through the crosslinking procedure, is to stop the progression of keratoconus at the earliest possible stage.
The method was researched and developed in Dresden in the 1990s.
TAD produced the first commercial CXL system on the market.
The new "TAD CXL" system is a further development, it offers the possibility to choose amongst significantly extended treatment parameters.